XOMA Ltd. announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially. Mr. Neal brings more than 25 years' experience forming and maximizing valuable business and technology collaborations globally and in bringing novel products and technologies to market.

XOMA Ltd. - Conference Presentation Calls

XOMA Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net income of $1,538,000 or $0.01 per basic and diluted share on total revenue of $27,423,000 against net loss of $20,362,000 or $0.15 per basic and diluted share on total revenue of $7,894,000 for the same period a year ago. Income from operations of $6,780,000 compared to loss from operations of $18,544,000 for the same period a year ago. Net income before taxes of $1,908,000 compared to net loss before taxes of $20,362,000 for the same period a year ago. The improvement in total revenue was primarily due to increased revenues as a result of the sale of the LUCENTIS(r) royalty interest and decreased operating expenses. For the nine months, the company reported net loss of $2,433,000 or $0.02 per basic and diluted share on total revenue of $76,833,000 against net loss of $55,227,000 or $0.42 per basic and diluted share on total revenue of $31,067,000 for the same period a year ago. Income from operations of $10,786,000 compared to loss from operations of $50,361,000 for the same period a year ago. Net income before taxes of $3,650,000 compared to net loss before taxes of $55,227,000 for the same period a year ago. Cash provided by operating activities was $11,500,000 compared with cash used in operating activities of $35,800,000 during the first nine months of 2008. This change is primarily due to license and collaborative fees and the sale of the LUCENTIS(r) royalty interest to Genentech. The company expects that cash used in operating activities for 2009 may range from $5 million to cash neutral or positive. This guidance is updated from its prior estimate that cash used in operating activities for 2009 may range from $15 million to cash neutral.